Abstract 4760
Background
HCC is the second leading cause of cancer-related deaths worldwide. Sorafenib (SFN) has been the backbone of advanced HCC treatment over the past decade. Since the mean age of HCC presentation is between 50 and 60 years, data on SFN use in the elderly patients (pts) remain scarce due to underrepresentation of this population in pivotal clinical trials. Thus, the treatment of elderly HCC pts represents a clinical challenge given the concomitance of advanced age with chronic hepatopathy, raising concerns about clinical benefit and increased toxicity in this subgroup. We analyzed a cohort of HCC pts with the aim of evaluating the efficacy and safety of SFN in this specific population.
Methods
A cohort of pts with advanced HCC treated with SFN was retrospectively evaluated. Pts were divided into 2 groups: (A) those younger than 70 years-old (y-o) and (B) those who were 70 y-o or older at the time of SFN initiation. Survival (OS) was calculated from the first day of SFN to death or last data record. Time to treatment failure (TTF) due to disease progression or toxicity was calculated from the first to the last day on SFN. TTF and OS were estimated using Kaplan-Meier and curves were compared by log-rank test.
Results
We analyzed 226 HCC pts treated with SFN from Oct-2007 to Jan-2017. Group B was comprised of 37 (16.4%) pts, median age 73.5 years (70-85), 75.7% male, 29.7% had HCV, 86.5% Child-Pugh A, 37.8% had extrahepatic spread. Reduced starting dose SFN (< 800 mg/d) was more common in Group B than in Group A (27% vs 11.8%, p = 0.026). No statistically significant differences in OS (7.9 vs 9.8 months, p = 0.534) or TTF (3.5 vs 4.3 months, p = 0.962) were detected between Groups A and B. The incidence of dermatologic adverse events (38.6% vs 34.1%, p = 0.596) and hypertension (7% vs 5%, p = 0.641) did not differ significantly between Groups A and B, respectively. Intolerance leading to SFN discontinuation occurred in 11% and 9.5% of pts in Groups A and B, respectively (p = 0.780).
Conclusions
Our findings suggest that the efficacy and the incidence of adverse events were similar in elderly HCC pts treated with SFN when compared to younger pts. Thus, age alone should not be used to determine the therapy of pts with advanced HCC being considered for SFN.
Clinical trial identification
Legal entity responsible for the study
Instituto do Câncer do Estado de São Paulo.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
G. Nader Marta: Travel expenses: Bayer. M.I. Braghiroli: Honoraria: MSD; Research funding: Bayer. J. Sabbaga: Consulting or advisory role: Bayer, MSD; Speaker\'s bureau: Roche, Bayer, MSD; Travel expenses: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract